1. Home
  2. Live Updates
  3. Astrazeneca enhertu

Live Breaking News & Updates on Astrazeneca enhertu

Stay informed with the latest breaking news from Astrazeneca enhertu on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Astrazeneca enhertu and stay connected to the pulse of your community

Rx Rundown: Vertex Pharmaceuticals, Bristol Myers Squibb, Novartis and more

Rx Rundown: Vertex Pharmaceuticals, Bristol Myers Squibb, Novartis and more
mmm-online.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mmm-online.com Daily Mail and Mail on Sunday newspapers.

Florida , United-states , Alachua , California , United-kingdom , Spain , Times-square , Spanish , British , Moonlake-immunotherapeutics , Daiichi-sankyo , Geoff-curtis

Versant-backed Firefly Bio wants to make the next generation of ADCs

BioPharma

California , United-states , Carolyn-bertozzi , Eli-lilly , Bernhard-geierstanger , Jerel-davis , Daiichi-sankyo , John-flygare , Scott-hirsch , Astrazeneca-enhertu , Bristol-myers-squibb , Genentech

GSK adds to ADC dealmaking with second Chinese biotech pact

BioPharma

United-states , China , American , Seagen-adcetris , Astrazeneca-enhertu , Eli-lilly , Bristol-myers , Hansoh-pharma , Pfizer , Bristol-myers-squibb , Merck-co , American-society-of-clinical-oncology

Bristol Myers pays $100M for a different kind of ADC

BioPharma

South-korea , Daejeon , Taejon-gwangyoksi , United-states , Boston , Massachusetts , American , Daiichi-sankyo , Seagen-adcetris , Joo-lee , Astrazeneca-enhertu , Bristol-myers

GlobalData : Novartis eyes HR+/HER2- early breast cancer market with NATALEE trial success, says GlobalData -November 01, 2023 at 10:35 am EDT

01 Nov, 2023 Novartis eyes HR+/HER2- early breast cancer market with NATALEE trial success, says GlobalData



Share


Print...

Thomas-wales , Astrazeneca-enhertu , Eli-lily-verzenio , Novarti-kisqali , National-comprehensive-cancer-network , European-medical-society-of-oncology , European-medical-society , Eli-lily , Oncology-analyst , Markets ,

Merck cancer drug deal caps pharma investment influx into 'ADC' field

BioPharma

France , Japan , Spain , Germany , German , Japanese , French , Eli-lilly , Daiichi-sankyo , Astrazeneca-enhertu , Roche-kadcyla , Mablink-bioscience

Jefferies upgrades this pharma stock, citing overlooked 'blockbuster' drug opportunities

Analyst Peter Welford said that Astrazeneca's R&D assets outside the oncology pipeline can offer "significant upside optionality."

Japan , Pascal-soriot , Daiichi-sankyo , Astrazeneca-enhertu , Peter-welford , Astrazeneca , Analyst-peter-welford , Breaking-news-markets , Stock-markets , Investment-strategy , Markets , Astrazeneca-plc

Cancer Drugs Market Size Is Anticipated To Reach US$ 257.8 Billion at a CAGR of 7.6% by 2030, Report by Coherent Market Insights |

Cancer Drugs Market Size Is Anticipated To Reach US$ 257.8 Billion at a CAGR of 7.6% by 2030, Report by Coherent Market Insights |
medgadget.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medgadget.com Daily Mail and Mail on Sunday newspapers.

Japan , United-states , India , United-kingdom , America , Merck-keytruda , Astrazeneca-enhertu , Merck-lynparza , Seagen-tivdak , Asia-pacific , Bristol-myers-squibb-opdualag , Roche-ltd

Antibody Drug Conjugate (ADC) Markets, 2035

Dublin, Aug. 24, 2023 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugate Market (7th Edition): Distribution by Target Disease Indication, Therapeutic Area,...

United-states , China , Dublin , Ireland , American , America , Roche-kadcyla , Immunomedic-trodelvy , Daiichi-sankyo-astrazeneca-enhertu , Astellas-pharma , Astrazeneca-enhertu , Daiichi-sankyo

Breast Cancer Therapy Tukysa Proves Successful In Late-Stage Trials

(CTN News) - In a late-stage study involving a subset of breast cancer patients, Seagen's therapy, Tukysa, was able to achieve its main goal............

United-states , Daiichi-sankyo-enhertu , Astrazeneca-enhertu , Roche-kadcyla , Daiichi-sankyo , Roche-herceptin , Pfizer ,